Two real-world studies published in The New England Journal of Medicine draw conflicting conclusions on the effectiveness of treatment regimens involving intravenous immunoglobulin and glucocorticoids for the treatment of multisystem inflammatory disease in children.
Add-on treatment with the JAK inhibitor tofacitinib reduces the risk for death or respiratory failure among hospitalized patients with COVID-19 pneumonia who are not receiving mechanical ventilation, shows the STOP-COVID trial.
The majority of patients with systemic lupus erythematosus and confirmed COVID-19 are able to produce a durable antibody response to the infection, despite the use of immunosuppressants, US research suggests.
Initial data from the COVAX Registry offer reassurance for patients with rheumatic and musculoskeletal diseases that adverse events with the COVID-19 vaccines are similar to those seen in the general population.
The addition of levilimab to methotrexate improves response rates among patients with rheumatoid arthritis who are resistant to methotrexate, show phase 3 SOLAR data presented in a poster at the EULAR 2021 Virtual Congress.